Mezzion Pharma Co.,Ltd.

KOSDAQ:A140410 Stock Report

Market Cap: ₩952.8b

Mezzion PharmaLtd Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Dean Park

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership6.4%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation

Nov 02
Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation

Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit

Sep 27
Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit

Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Jun 11
Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking

Mar 04
Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking

We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon

Feb 05
We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon

Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain

Dec 14
Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain

CEO

Dean Park (68 yo)

no data

Tenure

Mr. Dong Hyun Park, Dean is the Founder of Mezzion Pharma Co.,Ltd. (formerly known as Dong-A PharmTech Co. Ltd.) and also serves as its Chief Executive Officer and President. Mr. Park also founded and serv...

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:49
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mezzion Pharma Co.,Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jae Hoon ShinHanwha Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Seung Kyu JungKiwoom Securities Co., Ltd.